Regenerative Medicine

Stem-cell trial starts in the UK

Mesoblast Ltd of Australia has received clearance to start a Phase 2 trial of a new allogeneic stem-cell therapy in patients suffering acute heart attacks. The UK’s King’s College Hospital NHS Foundation Trust is one of the study sites.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

F-Star signs discovery pact with Merck Serono

F-Star GmbH of Vienna will discover engineered antibodies for three inflammatory targets supplied by Merck Serono SA of Geneva in a contract that is potentially worth €492 million plus tiered royalties on product sales.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Austria

Direct cellular reprogramming reported

Researchers at the Harvard Stem Cell Institute have reported the reprogramming of adult mouse skin cells directly into a type of motor neuron by a method which they say is more efficient than the process for creating induced pluripotent stem cells.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States

EU project to study cell and gene therapy in heart disease

The European Commission has awarded €5.3 million over four years to a consortium led by Ark Therapeutics Group Plc to investigate the possible use of gene and cell therapy, along with stents, in the treatment of coronary heart disease.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Roslin Cells and Pfizer sign stem-cell agreement

Roslin Cells Ltd has reached an agreement with Pfizer Inc giving the US multinational access to its pluripotent stem cell lines with a view to assessing their potential for specific clinical therapies. Financial terms were not disclosed.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States

Trials using hESC technology under way in US

Advanced Cell Technology Inc has announced the dosing of the first patients in each of its two Phase 1/2 clinical trials for eye disorders using retinal pigment epithelial cells derived from human embryonic stem cells (hESCs).

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States

New method for creating iPS cells

A new method for deriving induced pluripotent stem cells (iPSCs) from blood samples has been described in the journal, Blood. According to the authors, the approach could provide a new source of patient-specific cells for disease research and drug discovery.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United States

Sanofi takes option on hearing technology

Sanofi SA has entered into a two-year research collaboration with a small Netherlands-based company, Audion Therapeutics BV, to develop potential treatments for hearing loss by targeting progenitor cells in the inner ear with small molecule compounds.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Netherlands

ReNeuron in licencing deal with Schepens

ReNeuron Group Plc has upgraded its collaboration with the Schepens Eye Research Institute in the US with the signing of a patent and licensing deal giving it rights to develop and commercialise human retinal precursor cells (hRPCs).

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

UK licenses adult stem cell bank

In a major advance for personalised medicine, the UK Human Tissue Authority has authorised a new stem cell banking service that will extract adult stem cells from human blood samples and store them for up to 20 years for use against future disease.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

United Kingdom

Syndicate content